Capital A Wealth Management’s Biogen BIIB Stock Holding History

Capital A Wealth Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3	Closed	-$459	–	728
2024 Q4	$459	Buy	+3	New	+$506	﹤0.01%	665

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital A Wealth Management's BIIB Position: Q1 2025 in Review

Capital A Wealth Management sold out of Biogen (BIIB) in Q1 2025, closing a stake of 3 shares — an estimated $459 sold.

Capital A Wealth Management first reported a position in BIIB in Q4 2024 and held it in 1 quarter. The position peaked at $459 in Q4 2024. 883 funds tracked by Wall St. Rank hold BIIB as of Q1 2025.

Capital A Wealth Management reported no remaining Biogen position as of Q1 2025 after selling out during the quarter.
Capital A Wealth Management sold 3 Biogen shares in Q1 2025, an estimated $459.
Capital A Wealth Management first reported a position in Biogen in Q4 2024 and held it in 1 quarter.
Capital A Wealth Management's Biogen position peaked at $459 in Q4 2024.
883 funds tracked by Wall St. Rank held Biogen as of Q1 2025.

Based on Capital A Wealth Management's 13F filing for Q1 2025, filed 2 May 2025.